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Background: Recent studies have linked chemotherapy resistance to the altered expression of microRNAs
(miRNAs). Thus, miRNA-based approaches to modulating sensitivity to temozolomide (TMZ) may overcome
chemoresistance. The aim of the present study was to investigate whether miR-136 could modulates glioma cell
sensitivity to TMZ.
Methods: The proliferation of glioma U251 cell line was evaluated by MTT assay. The expression of astrocyte
elevated gene-1 (AEG-1)was detected by real‑time polymerase chain reaction (RT-PCR)and Western blot. The
luciferase reporter gene was used to test whether AEG-1 was the target of the miR-136.
Results: The MTT assay showed that U251 cells with miR-136 overexpression were significantly more sensitive to
the therapy of TMZ than control cells. Luciferase assays revealed that miR-136 directly targeted the 3’UTR of AEG-1.
qRT–PCR and western blotting analysis found that AEG-1 expression at the mRNA and protein levels decreased in
the miR-136 mimic-treatment group relative to control group. Downregulation of AEG-1 expression by siRNAs, U251
cells became more sensitive to the therapy of TMZ. In addition, the enhanced growth-inhibitory effect by the
miR-136 mimics transfection was enhanced after the addition of AEG-1 siRNA.
Conclusions: The present study provides the first evidence that miR-136 plays a key role in TMZ resistance by
targeting the AEG-1 protein in glioma cell line, suggesting that miR-136 can be used to predict a patient’s response
to TMZ therapy as well as serve as a novel potential maker for glioma therapy.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_173
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Glioma is the most common type of primary brain tumor,
originating in glial cells, with poor prognosis during the
past 40 years [1]. Approximately 20,000 new cases of
glioma are diagnosed in the United States every year[1].
Malignant gliomas, including glioblastoma multiforme
(GBM) and anaplastic astrocytomas are the most common
primary brain tumors [2]. GBM is a highly aggressive and
neurologically destructive tumor that frequently colonizes
the cerebral hemispheres. First-line postsurgical therapy* Correspondence: dr_wangzhifei@126.com
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unless otherwise stated.for GBM currently consists of temozolomide (TMZ)
combined with regional fractionated radiation followed by
TMZ alone [3]. TMZ acts by inhibiting the proliferation
of glioma cells and inducing apoptosis [4]. Although TMZ
is currently the most promising chemotherapy for GBM,
it is not always effective because of the intrinsic or acquired
chemoresistance of glioma cells.
MicroRNAs (miRNAs) are a type of endogenous non-
coding RNA, which are able to bind to the 3'-untrans-
lated region (3'-UTR) of their target mRNAs, eventually
causing mRNA degradation or translational repression
[5]. In previous decades, accumulating studies have
demonstrated that miRNAs act as key regulators in the
development and progression of various types of cancer,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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array expression profiling showed that miR-136 was
overexpressed in lung cancer [7]. miR-136 was also re-
ported to be markedly upregulated in the Jurkat cell line
and targeted tumor suppressor PTEN, suggesting a pos-
sible significance of miR-136 in cancer development and
progression [8,9]. Haapa-Paananen et al. found that the
expression of miR-136 was lower in glioma tissues than
that in normal brain tissues, suggesting that miR-136
might play a tumor-suppressive role in glioma [10].
Recent studies have linked chemotherapy resistance to
the altered expression of microRNAs (miRNAs) [11,12].
Thus, miRNA-based approaches to modulating sensitiv-
ity to TMZ may overcome chemoresistance.
Astrocyte elevated gene-1 (AEG-1), was originally
cloned as a novel human immunodeficiency virus
(HIV)-1- and tumor necrosis factor-α-inducible gene in
primary human fetal astrocytes (PHFA) [13]. Recent
studies indicated that AEG-1 expression was elevated in
some solid tumors including prostate, breast, esophageal
cancer, hepatocellular carcinoma(HCC) and neuroblast-
oma [14-18]. The study by Emdad et al. indicated that
AEG-1 might play a crucial role in the pathogenesis of
glioma and that AEG-1 could represent a viable poten-
tial target for malignant glioma therapy [19].
We found that miR-136 might modulate AEG-1 using
online prediction software Target Scan. Therefore, we
speculated that miR-136 might play an important role in
glioma chemoresistance by targeting AEG-1.
Methods
Cell culture and transfection
The human glioma cell line U251 was obtained from
the American Type Culture Collection, and were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100
units of penicillin/mL, and 100 ng of streptomycin/mL.
Transfection of U251 cells with plasmids, pre-miR-136
or scrambled pre -miR control (GenePharma, Shanghai,
China), was performed using Lipofectamine 2000 ac-
cording to the manufacturer's instructions (Invitrogen
Life Technologies, Carlsbad, CA, USA). Untransfected
U251 cells were employed as a negative control.
Total RNA extraction and real‑time polymerase chain
reaction (qRT-PCR). Total RNA was extracted from cells
using a modified TRIzol one‑step extraction method
(Invitrogen Life Technologies). Stem-loop reverse tran-
scription for mature miR-136 and U6 primers was per-
formed. U6 RNA was used as an miRNA internal control.
The primers used for stem-loop reverse -transcription PCR
for miR-136 were purchased from Guangzhou RiboBio Co.,
Ltd. (Guangzhou, China). Each sample was conducted in
triplicate and the results were calculated using the 2-ΔΔCt
method.MTT assay
Cells transfected with plasmids, pre-miR-136 or scram-
bled pre-miR control or AEG-1 siRNA, were seeded into
96-well plates at 6*103 cells/well and allowed to grow
overnight, and then were treated with different concentra-
tions of TMZ. After 24 h of treatment, 20ul of 5 mg/ml
MTT reagent (Sigma-Aldrich,St.Louis, MO, USA) was
added and incubated in the dark for 4 h. The absorbance
of the plate was measured in a microplate reader at a
wavelength of a 570-nm reference (BMG Lab Technolo-
gies, Germany), and the results were expressed as the
percentage of absorbance relative to untreated controls.
Each treatment was carried out in triplicate.Dual luciferase reporter assay
The construction of psiCHECK- AEG-1 and psiCHECK-
AEG-1mut 3’ UTRs was performed and verified by DNA
sequencing. A total of 293 T cells (5 × 104 per well) were
seeded into 24-well plates and allowed to attach overnight.
The cells were cotransfected with a 50 nM miR-136
mimic or control, as well as a 0.5ug reporter vector con-
taining either MEK1 3’UTRs or MEK1mut 3’ UTRs carry-
ing a mutational miR-136 binding site. After 48 h, cells
were harvested and lysed, and ratios between renilla and
firefly luciferase activity were estimated using the Dual
Luciferase Assay Kit (Promega) according to the manufac-
turer’s instructions. Data were presented as the mean
value of renilla/firefly luciferase ratios, obtained from at
least three independent experiments.Western blot assay
The proteins were resolved on an SDS denaturing poly-
acrylamide gel and then transferred onto a nitrocellu-
lose membrane. Antibody to AEG-1 or GAPDH was
incubated with the membranes overnight at 4°C. The
membranes were washed and incubated with horserad-
ish peroxidase (HRP)-conjugated secondary antibodies.
Protein expression was assessed by enhanced chemilu-
minescence and exposure to chemiluminescent film.
LabWorks™ Image Acquisition and Analysis Software
(UVP, Upland, CA) were used to quantify the band in-
tensities. All the antibodies were purchased from
Abcam (Cambridge, MA).Statistical analysis
All the data were shown as mean ± standard deviation
(SD) and the experiments.
Were repeated three times. The difference was deter-
mined by two-tailed students’ t-test and P < 0.05 was con-
sidered statistically significant. The data were assessed
using the GraphPad Prism software 5.0 (GraphPad, USA)
and SPSS version 18.0 (SPSS,Chicago, IL, USA).
Wu et al. Diagnostic Pathology 2014, 9:173 Page 3 of 6
http://www.diagnosticpathology.org/content/9/1/173Results
Overexpression of miR-136 correlates with cytotoxic
activity of TMZ in U251 cells
In order to explore the role of miR-136 in U251 cells,
transfection with plasmids, pre-miR-136 or scrambled
pre-miR control, was performed. The expression Levels
of miR −136 were confirmed by qPCR, as shown in
Figure 1A. Pre- miR-136 (miR −136) - transfected cells
showed a higher miR-136 expression than the untransfected
negative control (Con) and empty vector-transfected (miR-
Con) groups. To evaluate the effect of miR-136 on the
cytotoxic activity of TMZ in U251 cells, MTT assay was
performed on the pre- miR-136 transfected cells, the Con
and miR-Con groups combined with various concentrationsFigure 1 Effect of the overexpression of miR‑136 on the cytotoxic act
higher miR‑136 expression than the Con (P < 0.05) and miR-Con (P < 0.05) g
transfected cells and Con and miR-Con groups following treatment with TMof TMZ. The results showed that the viability of U251 cells
with miR-136 overexpression was significantly decreased
compared with that of the miR-Con group at the same con-
centration of TMZ (shown in Figure 1B). This indicated
that miR‑136 sensitized U251 cells to TMZ compared
with the Con group. This observation suggested that the
overexpression of miR-136 facilitated the cytotoxic activity
of TMZ in U251 cells.
AEG-1 was a target of miR-136
Predicted miR-136 targets were identified using the algo-
rithms of TargetScan and microRNA. Among hundreds of
potential target genes, we specifically focused on AEG-1,
as it has been consistently reported to be oncogene inivity of TMZ in U251 cells. (A) miR‑136‑transfected cells showed
roups. (B) Cell viability was detected by MTT assay in pre-miR-136
Z for 24 h.*P < 0.05.
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in the 3’-UTR of AEG-1 mRNA. To confirm that miR-136
can bind to the predicted site, we performed a luciferase
reporter assay in the 293 T cell line. Figure 2A showed
that the luciferase activity significantly decreased after co-Figure 2 AEG-1 was a direct target of miR-136. A: the luciferase
activity significantly decreased after co-transfection with psiCHECK-2/
AEG-1 3’-UTR and miR-136 mimics in comparison with control cells.
B: AEG-1 mRNA level was detected by qRT–PCR in U251 cells
transfected with miR-136 mimic or the control. C: AEG-1 protein
level was detected by Western blotting in U251 cells transfected
with miR-136 mimic or the control.transfection with psiCHECK-2/ AEG-1 3’-UTR and miR-
136 mimics in comparison with control cells. The results
demonstrated that miR-136 specifically binded to the 3’-
UTR of AEG-1 mRNA. The effect of miR-136 transfection
on AEG-1 mRNA and protein expression was respectively
assessed using qRT-PCR and Western blot in U251 cell
line. As shown in Figure 2B and C, the qRT–PCR and
western blotting analysis found that AEG-1 expression at
the mRNA and protein levels decreased in the miR-136
mimic-treatment group relative to NC.
AEG-1 was responsible for the miR-136-induced resistance
to TMZ in U251 cells
Downregulation of AEG-1 expression by siRNAs, U251
cells became more sensitive to the therapy of TMZ (shown
in Figure 3). In addition, the enhanced growth-inhibitory
effect by the miR-136 mimics transfection was enhanced
after the addition of AEG-1 siRNA(shown in Figure 3).
Discussion
TMZ, which inhibits glioma cell growth and induces
apoptosis, has been adopted as the first-line drug in
patients with glioma [20]. However, it has produced only
modest improvements in disease outcomes, attributed in
part to the presence of existing or de novo resistance to
chemotherapy in glioma patients. Therefore, it is worth-
while to select the correct anticancer drug to the right
cancer patient. Predictive markers, predicting a response,
often related to individually tailored therapy.
MicroRNAs, a class of small regulatory RNAs, have
been demonstrated to play important roles in a wide var-
iety of oncogenic activities, such as proliferation, invasion,
and angiogenesis [21]. Dysregulated miRNAs have been
observed in various kinds of tumors, including brain
tumors such as glioma and its aggressive glioblastoma
subtype [22]. Accumulating data indicate that miRNAs
are involved in advanced stages of cancer progression andFigure 3 Downregulation of AEG-1 expression by siRNAs, U251
cells became more sensitive to the therapy of TMZ. In addition, the
enhanced growth-inhibitory effect by the miR-136 mimics transfection
was enhanced after the addition of AEG-1 siRNA. *P< 0.05.
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Recent studies have strongly implicated aberrant miRNA
expression in anticancer drug resistance and sensitivity
[12,23,24]. In glioma, Shi et al. found that miR-124 inhib-
ited glioma cell growth, invasion, angiogenesis, and tumor
growth and increased chemosensitivity to TMZ treatment
by negatively regulating the Ras family and its down-
stream signaling pathways: phosphatidylinositol-3 kinase/
Akt and Raf/extracellular signal-regulated kinase 1/2 [25].
Wang et al. found that glioma cells rich in miR-181b were
more sensitive to TMZ therapy. miR-181b combined with
TMZ enhanced glioma cell sensitivity and apoptosis. The
effects were through post-transcriptional repression of
MEK1. Therefore, a combination of miR-181b and TMZ
might be an effective therapeutic strategy for gliomas [26].
Recently, miRNA microarray expression profiling showed
that miR-136 was overexpressed in lung cancer [7]. miR-
136 was also reported to be markedly upregulated in the
Jurkat cell line and targeted tumor suppressor PTEN, sug-
gesting a possible significance of miR-136 in cancer devel-
opment and progression [8,9]. Latter reports showed that
miR-136 was implicated in cancer biology and played roles
as both tumor suppressor and oncogene in different types
of cancer by targeting distinct genes. Haapa-Paananen
et al. found that the expression of miR-136 was lower in
glioma tissues than that in normal brain tissues, suggest-
ing that miR-136 might play a tumor-suppressive role in
glioma [10]. In the present study, to evaluate the effect of
miR-136 on the cytotoxic activity of TMZ in U251 cells,
MTT assay was performed on the pre- miR-136 trans-
fected cells, the Con and miR-Con groups combined with
various concentrations of TMZ. The results showed that
the viability of U251 cells with miR-136 overexpression
was significantly decreased compared with that of the
miR-Con group at the same concentration of TMZ, indi-
cating that miR‑136 sensitizes U251 cells to TMZ com-
pared with the Con group. This observation suggested
that the overexpression of miR-136 facilitates the cyto-
toxic activity of TMZ in U251 cells. As we know, many
onco-miRs/tumor suppressor-target or tumor suppressor-
miRs/onco-target pathways have been demonstrated to
participate in the tumorigenesis of glioma. However,
miRNA/target network was so complex that more and
more miRNA/target axis needs to be elucidated in glioma.
Predicted miR-136 targets were identified using the algo-
rithms of TargetScan and microRNA. Among hundreds of
potential target genes, we specifically focused on AEG-1,
as it has been consistently reported to be oncogene in
various cancers. Recent studies indicate that AEG-1 ex-
pression is elevated in some solid tumors including pros-
tate, breast, esophageal cancer, HCC and neuroblastoma
[14-18]. The study by Emdad et al. indicated that AEG-1
might play a crucial role in the pathogenesis of glioma and
that AEG-1 could represent a viable potential target formalignant glioma therapy[19]. In the present study, lucif-
erase assays revealed that miR-136 directly targeted the
3’UTR of AEG-1. In addition, qRT–PCR and western blot-
ting analysis found that AEG-1 expression at the mRNA
and protein levels decreased in the miR-136 mimic-
treatment group relative to control group. Furthermore,
downregulation of AEG-1 expression by siRNAs, U251
cells became more sensitive to the therapy of TMZ. In
addition, the enhanced growth-inhibitory effect by the
miR-136 mimics transfection was enhanced after the
addition of AEG-1 siRNA. These findings suggested that
AEG-1 was responsible for the miR-136-induced resist-
ance to TMZ. Our study might provide a useful strategy
to overcome TMZ resistance in glioma. The present find-
ings are needed to be further validated by in vivo experi-
ments and clinical studies. In addition, elucidation of role
of other miRNAs in TMZ resistance requires further
study.
Conclusion
In conclusions, the present study provides the first evi-
dence that miR-136 plays a key role in TMZ resistance
by targeting the AEG-1 protein in glioma cell line, sug-
gesting that miR-136 can be used to predict a patient’s
response to TMZ therapy as well as serve as a novel
potential maker for glioma therapy.
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